Scarica l'app Stockscreener
1.10
4.76%
0.05
Precedente Chiudi:
$1.05
Aprire:
$1.05
Volume 24 ore:
821.65K
Relative Volume:
1.54
Capitalizzazione di mercato:
$93.53M
Reddito:
$2.24M
Utile/perdita netta:
$-136.67M
Rapporto P/E:
-0.5069
EPS:
-2.17
Flusso di cassa netto:
$-102.08M
1 W Prestazione:
-9.84%
1M Prestazione:
-12.70%
6M Prestazione:
-59.11%
1 anno Prestazione:
-52.59%
Intervallo 1D:
$1.045
$1.12
Intervallo di 1 settimana:
$0.98
$1.255
Portata 52W:
$0.98
$5.51
Century Therapeutics Inc Stock (IPSC) Company Profile
Nome
Century Therapeutics Inc
Settore
Industria
Telefono
215-981-4000
Indirizzo
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Confronta IPSC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
1.10 | 93.53M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-08 | Iniziato | Rodman & Renshaw | Buy |
| 2023-08-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-12-27 | Iniziato | Chardan Capital Markets | Buy |
| 2022-10-31 | Iniziato | Guggenheim | Buy |
| 2022-10-10 | Iniziato | Canaccord Genuity | Buy |
| 2022-05-23 | Iniziato | H.C. Wainwright | Buy |
| 2022-05-12 | Iniziato | William Blair | Mkt Perform |
| 2021-07-13 | Iniziato | BofA Securities | Buy |
| 2021-07-13 | Iniziato | JP Morgan | Overweight |
| 2021-07-13 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Century Therapeutics Inc Borsa (IPSC) Ultime notizie
Charles Schwab Investment Management Inc. Sells 43,049 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Deal Watch: Merck Decides Better Late Than Never In GLP-1 Deal With Hansoh - Scrip
Philadelphia cell therapy developer loses Big Pharma partnership valued at over $3B - Philadelphia Business Journal
Layoff Tracker: Editas Will Cut 60% of Staff - BioSpace
BMS’ Cost-Cutting Campaign Claims Collabs With Immatics, Century - BioSpace
Century Therapeutics ends collaboration with Bristol-Myers Squibb - Investing.com
Century Therapeutics ends collaboration with Bristol-Myers Squibb By Investing.com - Investing.com UK
Fmr LLC Sells 428,768 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - MarketBeat
Fmr LLC Cuts Stake in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics Faces Termination of BMS Agreement - TipRanks
Century Therapeutics (NASDAQ:IPSC) Trading Down 4.3%Here's Why - MarketBeat
Likelihood of Approval and Phase Transition Success Rate ModelCNTY-101 in Systemic Lupus Erythematosus - GlobalData
Aclaris Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - MyChesCo
Century Therapeutics to Present at Piper Sandler 36th Annual Healthcare Conference - MyChesCo
Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Casdin Capital, LLC Increases Stake in Century Therapeutics Inc - GuruFocus.com
Comparing Century Therapeutics (NASDAQ:IPSC) & Prime Medicine (NYSE:PRME) - Defense World
Benitec Biopharma to Participate in Upcoming Investor Conferences in December - The Manila Times
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Century Therapeutics Expands Clinical Focus and Reports Steady Financials for Q3 2024 - MSN
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - The Malaysian Reserve
Endo, Inc. Partners with MC2 Therapeutics to Bring Wynzora® Cream to Canadian Market - MyChesCo
Syncona Portfolio Ltd's Strategic Acquisition of Autolus Therape - GuruFocus.com
FMR LLC's Strategic Reduction in Century Therapeutics Inc Holdin - GuruFocus.com
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Carisma Therapeutics and Moderna Unveil Promising Pre-Clinical Data for Anti-GPC3 CAR-M Therapy - MyChesCo
Century Therapeutics to Present Cutting-Edge Preclinical Data at 2024 ASH Annual Meeting - MSN
Ocugen Advances Gene Therapy and Financial Strategies in Q3 2024 - MyChesCo
William Blair Has Positive Estimate for IPSC FY2024 Earnings - Defense World
Palvella Therapeutics Begins Phase 3 Trial for Microcystic Lymphatic Malformations Treatment - MyChesCo
Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates - MSN
FY2024 Earnings Estimate for IPSC Issued By HC Wainwright - Defense World
Context Therapeutics Announces Q3 2024 Financial Results and Strategic Advances - MyChesCo
What Makes Century Therapeutics (IPSC) a New Buy Stock - Yahoo Finance
What is HC Wainwright's Forecast for IPSC FY2024 Earnings? - MarketBeat
William Blair Has Strong Estimate for IPSC FY2024 Earnings - MarketBeat
Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim's Healthcare Innovation Conference! - MyChesCo
Aclaris Therapeutics Highlights Key Advances and Financial Results for Q3 2024 - MyChesCo
Passage Bio CEO Will Chou to Share Insights at Guggenheim Healthcare Innovation Conference! - MyChesCo
Chardan Capital Has Lowered Expectations for Century Therapeutics (NASDAQ:IPSC) Stock Price - MarketBeat
Century Therapeutics, Inc. Demonstrates Strong Financial Management with No Senior Securities Defaults - TipRanks
Join Century Therapeutics at Guggenheim’s Healthcare Innovation Conference! - MyChesCo
Century Therapeutics shares target cut, retains Buy rating on updated data - Investing.com UK
HC Wainwright Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $5.00 - MarketBeat
Century Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Century Therapeutics COO sells $1,267 in stock - Investing.com
Century Therapeutics Reports Q3 Results & Strategic Updates - TipRanks
Century Therapeutics COO sells $1,267 in stock By Investing.com - Investing.com UK
Century Therapeutics earnings beat by $0.08, revenue topped estimates - Investing.com UK
InventHelp Inventor Develops Protective Accessory for Underwear (ASP-336) - Yahoo Finance
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times
Century Therapeutics Inc Azioni (IPSC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Century Therapeutics Inc Azioni (IPSC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Carr Douglas | SVP Finance & Operations |
Nov 04 '24 |
Sale |
1.23 |
283 |
347 |
317,147 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):